These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6695626)

  • 1. Interaction between estradiol, prolactin, and striatal dopaminergic mechanisms.
    Bédard P; Boucher R; Di Paolo T; Labrie F
    Adv Neurol; 1984; 40():489-95. PubMed ID: 6695626
    [No Abstract]   [Full Text] [Related]  

  • 2. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
    Chase TN; Konitsiotis S; Oh JD
    Adv Neurol; 2001; 86():355-60. PubMed ID: 11553996
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine D2(High) receptors on intact cells.
    Seeman P
    Synapse; 2008 Apr; 62(4):314-8. PubMed ID: 18241049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesis.
    Di Chiara G; Morelli M
    Adv Neurol; 1993; 60():102-6. PubMed ID: 8093571
    [No Abstract]   [Full Text] [Related]  

  • 5. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 6. Tetrabenazine has properties of a dopamine receptor antagonist.
    Login IS; Cronin MJ; MacLeod RM
    Ann Neurol; 1982 Sep; 12(3):257-62. PubMed ID: 7137960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 8. Sensitive periods for the effect of haloperidol on development of striatal dopamine receptors.
    Rosengarten H; Friedman E; Friedhoff AJ
    Birth Defects Orig Artic Ser; 1983; 19(4):511-3. PubMed ID: 6871420
    [No Abstract]   [Full Text] [Related]  

  • 9. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Schröder U; Schröder H; Augustin W; Sabel BA
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of estrogens and the dopaminergic system.
    Boissier JR; Euvrard C; Labrie F
    Acta Physiol Pharmacol Bulg; 1982; 8(1-2):50-7. PubMed ID: 7124419
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
    Anglade P; Tsuji S; Javoy-Agid F; Agid Y; Hirsch EC
    Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction.
    Costa RM; Lin SC; Sotnikova TD; Cyr M; Gainetdinov RR; Caron MG; Nicolelis MA
    Neuron; 2006 Oct; 52(2):359-69. PubMed ID: 17046697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of striatal dopamine in the lordosis behaviour.
    Pednekar JR; Mascarenhas JF
    Indian J Physiol Pharmacol; 1993 Oct; 37(4):333-6. PubMed ID: 8112812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms compensating for dopamine loss in early Parkinson disease.
    Brotchie J; Fitzer-Attas C
    Neurology; 2009 Feb; 72(7 Suppl):S32-8. PubMed ID: 19221312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dopaminergic nigrostriatal system: development, physiology, disease.
    von Bohlen Und Halbach O; Krieglstein K; Schober A; Schulz JB
    Cell Tissue Res; 2004 Oct; 318(1):3. PubMed ID: 15340830
    [No Abstract]   [Full Text] [Related]  

  • 17. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aging and the regulation of striatal dopaminergic mechanisms in mice.
    Randall PK; Severson JA; Finch CE
    J Pharmacol Exp Ther; 1981 Dec; 219(3):695-700. PubMed ID: 7197719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of age on dopaminergic supersensitivity induced by chronic fluphenazine.
    Misra CH; Smith RC
    Commun Psychopharmacol; 1980; 4(5):411-5. PubMed ID: 7333094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.